intrathecal bolus trials of ziconotide for cancer related pain
Download
Skip this Video
Download Presentation
Intrathecal Bolus Trials of Ziconotide for Cancer-Related Pain

Loading in 2 Seconds...

play fullscreen
1 / 11

Intrathecal Bolus Trials of Ziconotide for Cancer-Related Pain - PowerPoint PPT Presentation


  • 204 Views
  • Uploaded on

Intrathecal Bolus Trials of Ziconotide for Cancer-Related Pain. Mitchell Engle M.D., Ph.D. Obinna Uzodinma , M.D. Brian Bruel , M.D., M.B.A MD Anderson Cancer Center Houston, TX. Disclosures. ME None OU None BB Consultant for Jazz Pharmaceuticals Consultant for Medtronic.

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'Intrathecal Bolus Trials of Ziconotide for Cancer-Related Pain' - ashtyn


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
intrathecal bolus trials of ziconotide for cancer related pain

Intrathecal Bolus Trials of Ziconotide for Cancer-Related Pain

Mitchell Engle M.D., Ph.D.

ObinnaUzodinma, M.D.

Brian Bruel, M.D., M.B.A

MD Anderson Cancer Center

Houston, TX

disclosures
Disclosures
  • ME
    • None
  • OU
    • None
  • BB
    • Consultant for Jazz Pharmaceuticals
    • Consultant for Medtronic
ziconotide
Ziconotide
  • Synthetic selective N-type Calcium Channel blocker
  • Problem: Poor pain control in cancer patients despite high dose opioid and adjuvant medications
  • Objective: Demonstrate that single shot intrathecal trials of ziconotide effectively reduce cancer related pain
study design
Study Design
  • Retrospective chart review
  • Three year time period (2009-2012)
  • Single shot bolus trials of ziconotide
    • Both mono- and combination trials
  • Pre-trial and 24 hr post-procedure numeric pain scores
  • Successful trial: > 30% numeric pain score reduction
  • Etiology of pain was tumor or cancer related treatments
demographic data
Demographic Data
  • 40 individual patients
    • 44 independent trials

Tumor Related

27

Treatment Related

14

Other

3

ziconotide doses
Ziconotide Doses

Mean (mcg)

2.6

2.5

2.7

N

40

30

10

combination effects
Combination Effects

Successful Trials

Failed Trials

Ziconotide alone

+Bupivacaine

Ziconotide alone

+Bupivacaine

Zicono (mcg)

2.8

2.5

2.8

2.6

Bupiv (mg)

2.2

1.8

N

12

16

5

5

diagnoses of successful trials
Diagnoses of Successful Trials

Metastatic Disease

10

Metastasis to Spine

10

3

Post-laminectomy Pain

2

Locally Advanced Disease

1

CIPN

1

Compression Fractures

3

Other

conclusions
Conclusions
  • Single shot intrathecalziconotide produces robust analgesia in cancer pain patients
  • The average dose of ziconotide for successful trials was approximately 2.5 mcg
  • Bupivacaine did not appear to produce an additive or synergistic effect for ziconotide
  • Ziconotide successfully produced analgesia in patients with metastatic cancer pain, chronic post-surgical pain, and CIPN.
ad